In 2021, Teva in partnership with the 6th All-Russian GMP Conference involving international participants will present its experience and participate in discussions at the St. Petersburg site.
Teva is one of the leaders in the global pharmaceutical industry and one of the world’s leading manufacturers of generics. The company is headquartered in Israel and its medicines are available in 100 countries around the world. The product portfolio includes over 1,800 molecules and the widest range of therapeutic applications. With a portfolio of more than 300 products, Teva also tops the Russian market.
The quality of the company’s products is confirmed by GMP (Good Manufacturing Practice), EMA (European Medicines Agency), and FDA (US Food and Drug Administration) certificates.
In 2014, Teva launched a plant in the Yaroslavl Region with a production capacity of up to 2 billion tablets per year. In 2016, Teva was one of the first companies to apply for GMP inspections.
In 2021, as per the Global Strategy for Operations, the production site was sold to a local partner subject to retaining the maximum number of employees and continuing to operate as a contract manufacturer of Teva medicines in Russia.
Teva is still engaged in the production of five pharmaceuticals at the partner’s production site in the Yaroslavl Region. Due to participation in cutting-edge initiatives, the latest opinion of the company’s specialists is highly valued among the industry.
Margarita Mustafina, QA Manager for Russia and Eurasia at Teva, has repeatedly acted as a speaker at the GMP conference, expressing her opinion on issues such as drug labelling within the EAEU, correlation of Eurasian and national requirements, implementation of good practices at all production cycle stages, etc.
Teva is a strong expert not only in manufacturing, but also in compliance with good laboratory practices (GLP) and good clinical practices (GCP), the implementation of which is actively discussed in Russia.
The company strives to improve patients’ health and life quality through the development and launch of medicines that meet the highest quality and safety criteria.